Venus Concept to Release First Quarter of Fiscal Year 2025 Financial Results on May 15, 2025
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Venus Concept (NASDAQ: VERO), a global medical aesthetic technology leader, has scheduled the release of its first quarter fiscal year 2025 financial results for Thursday, May 15, 2025, before market opening. The company will host a conference call at 8:00 a.m. Eastern Time on the same day, featuring a management discussion and Q&A session.
Interested participants can join via phone using the access code 13753054: domestic callers can dial 877-407-2991, while international callers should use 201-389-0925. A live webcast will be available on the company's investor relations website. A two-week replay will be accessible using the same access code: 877-660-6853 for domestic and 201-612-7415 for international callers.
Details
News Market Reaction – VERO
The recorded move for VERO in the trading session of this news was +4.24%.
Data tracked by StockTitan Argus. Session date unavailable.
AI-generated analysis. How Rhea-AI works. Not financial advice.
TORONTO, April 07, 2025 (GLOBE NEWSWIRE) -- Venus Concept Inc. (“Venus Concept” or the “Company”) (NASDAQ: VERO), a global medical aesthetic technology leader, announced today that first quarter of fiscal year 2025 financial results will be released before the market opens on Thursday, May 15, 2025.
Management will host a conference call at 8:00 a.m. Eastern Time on May 15, 2025 to discuss the results of the quarter and host a question and answer session. Those who would like to participate may dial 877-407-2991 (201-389-0925 for international callers) and provide access code 13753054. A live webcast of the call will also be provided on the investor relations section of the Company's website at ir.venusconcept.com.
For those unable to participate, a replay of the call will be available for two weeks at: 877-660-6853 (201-612-7415 for international callers); access code 13753054. The webcast will be archived at ir.venusconcept.com.
About Venus Concept
Venus Concept is an innovative global medical aesthetic technology leader with a broad product portfolio of minimally invasive and non-invasive medical aesthetic and hair restoration technologies and reaches over 60 countries and 12 direct markets. Venus Concept's product portfolio consists of aesthetic device platforms, including Venus Versa, Venus Versa PRO, Venus Legacy, Venus Velocity, Venus Viva, Venus Glow, Venus Bliss, Venus Bliss MAX, Venus Epileve, Venus Viva MD and AI.ME. Venus Concept's hair restoration systems include NeoGraft® and the ARTAS iX® Robotic Hair Restoration system. Venus Concept has been backed by leading healthcare industry growth equity investors including EW Healthcare Partners (formerly Essex Woodlands), HealthQuest Capital, Longitude Capital Management, Aperture Venture Partners, and Masters Special Situations.

Investor Relations Contact: ICR Healthcare on behalf of Venus Concept Mike Piccinino, CFA VenusConceptIR@ICRHealthcare.com
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.